• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein

tetano

Editor, Senior Moderator
ACS Infect Dis. 2015 Feb 13;1(2):98-109. Epub 2014 Dec 15.
[h=1]A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein.[/h] White KM[SUP]1[/SUP], De Jesus P[SUP]2[/SUP], Chen Z[SUP]3[/SUP], Abreu P Jr[SUP]1[/SUP], Barile E[SUP]2[/SUP], Mak PA[SUP]3[/SUP], Anderson P[SUP]3[/SUP], Nguyen QT[SUP]2[/SUP], Inoue A[SUP]2[/SUP], Stertz S[SUP]1[/SUP], Koenig R[SUP]2[/SUP], Pellecchia M[SUP]2[/SUP], Palese P[SUP]1[/SUP], Kuhen K[SUP]3[/SUP], Garc?a-Sastre A[SUP]1[/SUP], Chanda SK[SUP]2[/SUP], Shaw ML[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] An ultrahigh-throughput screen was performed to identify novel small molecule inhibitors of influenza virus replication. The screen employed a recombinant influenza A/WSN/33 virus expressing Renilla luciferase and yielded a hit rate of 0.5%, of which the vast majority showed little cytotoxicity at the inhibitory concentration. One of the top hits from this screen, designated S20, inhibits HA-mediated membrane fusion. S20 shows potent antiviral activity (IC[SUB]50[/SUB] = 80 nM) and low toxicity (CC[SUB]50[/SUB] = 40 μM), yielding a selectivity index of 500 and functionality against all of the group 1 influenza A viruses tested in this study, including the pandemic H1N1 and avian H5N1 viruses. Mechanism of action studies proved a direct S20-HA interaction and showed that S20 inhibits fusion by stabilizing the prefusion conformation of HA. In silico docking studies were performed, and the predicted binding site in HA2 corresponds with the area where resistance mutations occurred and correlates with the known role of this region in fusion. This high-throughput screen has yielded many promising new lead compounds, including S20, which will potentially shed light on the molecular mechanisms of viral infection and serve as research tools or be developed for clinical use as antivirals.


[h=4]KEYWORDS:[/h] antiviral; docking; fusion; hemagglutinin; influenza; screen

PMID: 25984567 [PubMed] PMCID: PMC4426349 Free PMC Article
 
Back
Top Bottom